Divisadero Street Capital Management LP Has $93,000 Position in Neuronetics, Inc. (NASDAQ:STIM)

Divisadero Street Capital Management LP decreased its holdings in shares of Neuronetics, Inc. (NASDAQ:STIM) by 96.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,608 shares of the company’s stock after selling 1,487,839 shares during the period. Divisadero Street Capital Management LP owned approximately 0.17% of Neuronetics worth $93,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in shares of Neuronetics during the first quarter worth about $62,000. Dorsey & Whitney Trust CO LLC raised its holdings in shares of Neuronetics by 53.0% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 48,652 shares of the company’s stock valued at $232,000 after purchasing an additional 16,855 shares during the last quarter. Legato Capital Management LLC bought a new position in shares of Neuronetics during the second quarter valued at about $44,000. FourWorld Capital Management LLC purchased a new position in Neuronetics during the first quarter worth about $171,000. Finally, Silvercrest Asset Management Group LLC grew its position in Neuronetics by 4.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 1,178,365 shares of the company’s stock worth $5,609,000 after purchasing an additional 51,881 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Neuronetics Price Performance

Shares of NASDAQ STIM opened at $0.95 on Friday. The stock has a fifty day moving average of $1.31 and a 200-day moving average of $2.44. The stock has a market cap of $28.71 million, a PE ratio of -0.99 and a beta of 2.27. The company has a debt-to-equity ratio of 2.38, a quick ratio of 2.37 and a current ratio of 2.58. Neuronetics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $5.07.

Neuronetics (NASDAQ:STIM) last posted its earnings results on Monday, August 12th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. The company had revenue of $16.45 million for the quarter, compared to analysts’ expectations of $18.76 million. During the same period in the previous year, the firm earned ($0.17) EPS. Equities research analysts anticipate that Neuronetics, Inc. will post -0.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. William Blair restated a “market perform” rating on shares of Neuronetics in a research note on Monday, August 12th. JMP Securities cut their price objective on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. Finally, Canaccord Genuity Group lowered their price target on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th.

Insider Buying and Selling

In other news, Director Robert Cascella purchased 100,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $0.75 per share, with a total value of $75,000.00. Following the completion of the acquisition, the director now owns 453,098 shares in the company, valued at approximately $339,823.50. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other Neuronetics news, Director Robert Cascella bought 100,000 shares of Neuronetics stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $0.75 per share, for a total transaction of $75,000.00. Following the completion of the transaction, the director now directly owns 453,098 shares in the company, valued at $339,823.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Keith J. Sullivan sold 24,162 shares of the firm’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $1.90, for a total value of $45,907.80. Following the completion of the sale, the chief executive officer now directly owns 1,324,354 shares in the company, valued at approximately $2,516,272.60. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 211,776 shares of company stock valued at $175,170. Company insiders own 9.80% of the company’s stock.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.